Results 71 to 80 of about 77,084 (260)

Macrophage PARP7 Alleviates Septic Cardiomyopathy by Interacting With TBK1 and Suppressing TBK1‐Driven Inflammatory Response

Advanced Science, EarlyView.
In septic cardiomyopathy, PARP7 directly binds TBK1 and mediates its ADP‐ribosylation, thereby repressing TBK1‐driven proinflammatory signaling in macrophages. ABSTRACT Septic cardiomyopathy is a life‐threatening complication of sepsis, and an uncontrolled inflammatory response represents a key pathogenic mechanism. PARP7 negatively regulates the IFN‐I
Jibo Han, Lintao Wang, Xin Zhong, Shenggang Zhao, Huihui Xie, Xue Han, Liming Lin, Yiting Lyu, Ke Xu, Jiajun Xu, Xiaowen Shi   +10 more
wiley   +1 more source

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Frontiers in Immunology
ObjectiveSeveral clinical trials have explored the efficacy and safety of Poly (ADP-ribose) polymerase (PARP) inhibitors in endometrial cancer (EC). However, evidence supporting PARP inhibitors alone or in combination with other medications in advanced ...
Huanhuan Zhang, Huanhuan Zhang, Guangwei Yan, Guangwei Yan, Jinxiang Yan, Jinxiang Yan, Xianxu Zeng, Xianxu Zeng   +7 more
doaj   +1 more source

Nuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1–JUN/FOS Axis

Advanced Science, EarlyView.
Genomic amplification drives aberrant nuclear localization of IDH3A in melanoma. Independent of its canonical metabolic activity, nuclear IDH3A cooperates with YBX1 to activate the c‐JUN/c‐FOS transcriptional program, while NONO facilitates its nuclear localization.
Juan Ran, Yanchun Fang, Shengming Ruan, Juling Wang, Songbai Liu, Yuan Mao, Dongsheng Hou, Yanping Wang, Zi Ye, Qiong Li, Daoxiang Zhang   +10 more
wiley   +1 more source

Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors

Nature Communications
For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied.
Carmen R. Moncayo, Restuadi Restuadi, Guanying Zhang, Daniel Marks, Paula Ortega-Prieto, Emily Doherty, Nathalie Lambie, Chad Whilding, Ivan Andrew, Alex Montoya, Bhavik Patel, Katie Tyson, Betheney R. Pennycook, Lauren Pendergast, Vincen Wu, Zoltan Takats, Nik Matthews, George R. Young, Priyanka Verma, Pavel Shliaha, Laurence Game, Boris Lenhard, Iain McNeish, Christina Fotopoulou, Alexis R. Barr, Paula Cunnea, Zoe Hall, Louise Fets   +27 more
doaj   +1 more source

Developing Highly Effective Nanoparticle mRNA Therapeutic for Pediatric Acute Respiratory Distress Syndrome

Advanced Science, EarlyView.
Sepsis‑induced pediatric acute respiratory distress syndrome suppresses FOXF1 in lung endothelial cells which causes life‐threatening lung damage. To counter this, researchers developed nanoparticles that specifically target these cells and deliver FOXF1 mRNA.
Zicheng Deng, Wen Gao, Jonathan Do, Danli Lu, Ying‐Wei Lan, Andreas Damianos, Gautam Verma, Ali Al Siraj, Isabella Lowry, Lance Peter, Nicholas E. Banovich, Fei Sun, Hua He, Tanya V. Kalin, Vladimir V. Kalinichenko   +14 more
wiley   +1 more source

MAP2K6 reprograms NAD+ metabolism via the HMGA1–NAMPT axis to sensitize ovarian cancer cells to PARP inhibition

Cell Death and Disease
PARP inhibitors (PARPi) selectively target cancers with homologous recombination deficiency (HRD), yet emerging evidence suggests that additional determinants beyond BRCA/HRD status modulate PARPi response.
Ming Wen, Zhuohang Chen, Dongdong Zhan, Mingwei Liu, Shuran Tan, Fang Zhu, Siyu Yang, Jinru Xie, Yu Zhang, Jianjian Li, Lunquan Sun, Rong Tan   +11 more
doaj   +1 more source

Glutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors

Advanced Science, EarlyView.
An injectable bimodal TCPD nanodepot disrupts glutaminolysis and TCA metabolism, sensitizing large tumors to spatially complementary sono‐thermal ablation for complete treatment coverage. This intervention induces mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD+ depletion, converging to trigger PANoptosome assembly and ...
Yi‐Ming Liu, Juan Qin, Si‐Yuan Wu, Xue‐Zhen Zhu, Yun‐Fei Cai, Pei‐Yao Sun, Hao Yang, Xing‐Yue Wang, Shu Li, Duo Wang, Hai‐Dong Zhu   +10 more
wiley   +1 more source

Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation

Journal of Bone Oncology, 2019
Chondrosarcoma is a malignant tumor that arises from cartilaginous tissue and is radioresistant and chemoresistant to conventional treatments. The preferred treatment consists of surgical resection, which might cause severe disabilities for the patient ...
Mathieu Césaire, Utpal Ghosh, Jean-Baptiste Austry, Etienne Muller, Francesco Paolo Cammarata, Marilyne Guillamin, Massimo Caruso, Laurent Castéra, Giada Petringa, Giuseppe Antonio Pablo Cirrone, François Chevalier   +10 more
doaj   +1 more source

Molecular Landscapes of Tumor Dormancy in Gynecologic Malignancies: From Survival Mechanisms to Precision Interception

Advanced Science, EarlyView.
This Review outlines the biological framework of entry, maintenance, and awakening in dormant minimal residual disease across gynecologic cancers. By mapping critical biological dependencies—from metabolic plasticity to microenvironment interactions—it evaluates novel interception concepts and presents a translational framework combining single‐cell ...
Shih‐Hsuan Cheng, Ren‐Wang Peng, Chang‐Cheng Wu, Chi‐Wen Luo, Emmanuel Naveen Raj, Zhi‐Hong Wen, Tzu‐Hung Hsiao, Chia‐Jung Li   +7 more
wiley   +1 more source

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

PLoS ONE, 2018
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging.
Z Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, Jake Moscarelli, Amy Xiong, Yasmin Korayem, Pamela H Huang, Smith Giri, Patricia LoRusso, Elena S Ratner   +9 more
doaj   +1 more source